Engitix Therapeutics
Christopher Stevenson currently serves as the Chief Scientific Officer at Engitix Therapeutics since September 2023. Previously, Stevenson held significant roles at Johnson & Johnson, including Vice President and Global Head of Pharmaceutical Sciences for Interventional Oncology, and Venture Leader in COPD & Lung Cancer within the Disease Interception Accelerator. Stevenson's academic contributions include honorary professorship at the University of Southern Denmark and roles at Imperial College London. Additionally, Stevenson has extensive experience in translational biology and respiratory pharmacology, having led initiatives at renowned organizations such as Roche and Novartis Institutes for Biomedical Research. Stevenson earned a PhD in Pharmacology from UC Santa Barbara in 2002.
Engitix Therapeutics
To create a healthier future for patients with life-threatening diseases, Engitix Therapeutics is using its pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumors.